Lensar integrating phacoemulsification technology from Oertli Instrumente AG into adaptive cataract treatment system
Surgeons can save space and optimise workflow efficiency in the operating room
CEO of Lensar, Nick Curtis, said the company was pleased to offer Oertli's phaco technology as an option to their customers.
Image credit: ©Mongkolchon – stock.adobe.com
On Monday, Lensar Inc. announced a step forward in its plans to integrate phacoemulsification technology from Oertli Instrumente AG, a Swiss manufacturer and industry leader in phacoemulsification, into the ALLY adaptive cataract treatment system.
According to a news release, Oertli filed an 510(k) with the FDA for its Faros device, which if cleared, will bring Lensar a step closer to deliver combined femto phaco technology. Lensar noted in its news release the combined femtosecond laser and phacoemulsification system will be the first system to combine these technologies, changing the paradigm in cataract surgery.
The current ALLY system has quickly gained adoption among cataract surgeons for its advantages in efficiency and clinical results. Surgeons have the option of performing FLACS procedures in a completely sterile environment, moving from laser to phaco, saving between 8 and 10 minutes per procedure with ALLY. With the combined system surgeons will also save space in the operating room and optimise cataract surgery, all on one system.
Nick Curtis, CEO of Lensar, said the company was pleased to present the phaco technology, developed by Oertli, as an option to their customers.
“This combined system will be the first ever on the market, demonstrating our commitment to change the paradigm in cataract surgery,” he said in the company’s news release. “ALLY will offer even more ways for surgeons to optimise their workflow and improve the patient experience.”
